Search Results

You are looking at 1 - 10 of 292 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Neoadjuvant Chemotherapy in Stage III NSCLC

Jeffrey Allen and Mohammad Jahanzeb

Edited by Kerrin G. Robinson

lung cancer (NSCLC): follow-up on a phase III trial [abstract] . J Clin Oncol 2007 ; 25 ( Suppl 1 ): 7520 . 30. Sorensen JB Riska H Ravn J . Scandinavian phase III trial of neoadjuvant chemotherapy in NSCLC stages IB-IIIA/T3 [abstract

Full access

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer

Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, and Aditya Bardia

young women with breast cancer. Neoadjuvant chemotherapy (NAC) is being increasingly used in the management of localized breast cancer as an alternative to adjuvant chemotherapy. Studies have shown that the benefit of chemotherapy is similar when given

Full access

Predictors of Locoregional Recurrence After Failure to Achieve Pathologic Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma, and Imran Zoberi

advanced TNBC typically receive chemotherapy, surgery, and radiation therapy (RT). More recently, the concept of neoadjuvant chemotherapy (NAC) followed by surgery and RT has been introduced in women with locally advanced or palpable TNBC, 6 because TNBC

Full access

Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Presented by: Joyce F. Liu

, Harvard Medical School, and member of the NCCN Guidelines Panel for Ovarian Cancer. The approach to initial treatment should consider several factors: Is there a place for neoadjuvant chemotherapy or intraperitoneal chemotherapy? Could the patient

Full access

Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy

William R. Kennedy, Christopher Tricarico, Prashant Gabani, Ashley A. Weiner, Michael B. Altman, Laura L. Ochoa, Maria A. Thomas, Julie A. Margenthaler, Souzan Sanati, Lindsay L. Peterson, Cynthia X. Ma, Foluso O. Ademuyiwa, and Imran Zoberi

, management has changed little because TNBC is typically still treated as a single disease entity. With the increasing use of neoadjuvant chemotherapy (NAC), one factor that has emerged as an indicator of responsiveness to standard therapy has been the

Full access

Inflammatory Breast Cancer

Holly Dushkin and Massimo Cristofanilli

version of these guidelines, visit the NCCN Web site at www.NCCN.org ) list the standard approach to treating IBC as neoadjuvant chemotherapy with an anthracycline-based regimen and a taxane. If HER2 is overexpressed, trastuzumab for a total of 1 year is

Full access

Low Rates of Chemotherapy Use for Primary, High-Grade Soft Tissue Sarcoma: A National Cancer Database Analysis

Danielle S. Graham, Mykola Onyshchenko, Mark A. Eckardt, Benjamin J. DiPardo, Sriram Venigalla, Scott D. Nelson, Bartosz Chmielowski, Arun S. Singh, Jacob E. Shabason, Fritz C. Eilber, and Anusha Kalbasi

neoadjuvant chemotherapy use in the setting of equivocal evidence for the treatment of adult patients with primary high-grade STS. Furthermore, we sought to characterize the factors associated with the use of each of these treatment regimens at Commission on

Full access

A Case of Unusual Mast Cell Response With Interstitial Cystitis-Like Symptoms to Neoadjuvant Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Bladder

Venkata Pokuri, Norbert Sule, Yousef Soofi, Bo Xu, Khurshid Guru, and Saby George

-based neoadjuvant chemotherapy has been shown to improve survival in patients with localized muscle-invasive bladder cancer. 2 - 5 In the metastatic setting, gemcitabine/cisplatin (GC) showed similar efficacy to MVAC (methotrexate

Full access

Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response

Margaret M. Kozak, Clare E. Jacobson, Rie von Eyben, Erqi L. Pollom, Melinda Telli, and Kathleen C. Horst

-positive and triple-negative breast cancer (TNBC) in this group, these women are also more likely to have pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC), 7 – 9 which has been extensively studied as a surrogate marker for

Full access

Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA

Li-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Yang Li, Qing-Nan Tang, Xue-Song Sun, Yu-Jing Liang, Chong Zhao, Xiang Guo, Chao-Nan Qian, Mu-Sheng Zeng, Jin-Xin Bei, Ming-Huang Hong, Jian-Yong Shao, Ying Sun, Jun Ma, and Hai-Qiang Mai

, concurrent chemoradiotherapy; EBV, Epstein-Barr virus; NACT, neoadjuvant chemotherapy; NPC, nasopharyngeal carcinoma. Pretreatment Evaluation All patients underwent a complete physical examination, fiberoptic nasopharyngoscopy, electrocardiography, MRI of the